- Visual impairment is a significant health and economic problem worldwide.
- The estimated number of people visually impaired in the world is 285 million, 39 million blind and 256 million having low vision. 65% of people visually impaired and 82% of all blind are 50 years and older.
- The global cost of vision loss is nearly £2.46 trillion for the 733 million people living with low vision and blindness worldwide in 2010.
- Every day around 100 people in the UK start to lose their sight.
Our Solution – OcuLief™
Our aim is to overcome the current need for monthly injection of medicine to treat chronic eye diseases (e.g. AMD). OcuLief is tailored for the treatment of AMD, DR and DME by long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months.
In situ forming photo-crosslinked intravitreal OcuLief™ implant
Advantages of OcuLief™
Drug-loaded gels can be administered using conventional hypodermic needles (e.g. 27G or smaller)
Materials used in implant preparation are biocompatible & biodegradable
Allows localised drug delivery at various sites within and around the eye
Sustained and tailored drug delivery for up to 12 months
Ability to deliver wide range of molecules, including proteins and peptides
Simple and scalable formulation approach